New Report shows investment in malaria prevention paying off

A new report confirms that the current global investment in malaria control is saving lives and that further increases in funding will contribute significantly to achieving the Millennium Development Goals (MDGs) for health. Saving Lives with Malaria Control: Counting Down to the Millennium Development Goals - authored by Tulane University, Johns Hopkins University, WHO and PATH and published by the Roll Back Malaria Partnership (RBM) - reveals that the lives of almost three quarters of a million children in 34 African countries are estimated to have been saved in the past 10 years, through the use of insecticide treated mosquito nets, indoor residual spraying, and preventive treatment of malaria during pregnancy.

The report estimates that an additional 3 million lives could be saved by 2015 if the world continues to increase investment in tackling the disease.

Malaria causes over 850,000 deaths per year worldwide, the majority of deaths in Africa where the disease accounts for almost 20% of all child deaths. Malaria also threatens the health of pregnant women. In sub-Saharan Africa, as many as 10,000 pregnant women die each year of malaria-related causes, mainly anaemia.

Massive increases in the availability of insecticide treated nets have been recorded in the last few years. However, directly measuring the impact of insecticide nets, treatments and other malaria control efforts is difficult as health information systems remain weak, and the majority of malaria deaths are not properly recorded.

The Lives Saved Tool (LiST) - developed to be used across major childhood diseases - is being applied to malaria prevention across Africa. The report provides the first assessment of lives saved based on the level of coverage achieved with currently available malaria prevention tools. Although this does not include data on lives saved from diagnosis and treatment, and is likely to be an underestimate, the results show just how much progress has been made.

"The findings from this report clearly show the efficacy of our efforts to save lives, especially among children in Africa," says Professor Awa Coll Seck, RBM Partnership Executive Director. "This is a vital tool which can help strengthen country planning and guide us all as we focus on 2015." Findings from the report also show that the number of rural households protected by either insecticide-treated nets or indoor residual spraying has increased significantly, especially in the latter half of this decade. The report estimates that malaria funding in 2010 could result in 500 more children alive every day.

"This report demonstrates the critical importance of malaria control efforts to reaching the healthrelated Millennium Development Goals by 2015" states Dr Robert Newman, director of the Global Malaria Programme at WHO. "Without continued investment in malaria, reaching the MDG for child survival is unlikely to be reached in Africa."

"While we've made great progress, much work remains", said Rear Admiral (Ret.) Tim Ziemer, U.S. Global Malaria Coordinator. "To reach the Millennium Development Goals, we must accelerate our efforts to expand not only malaria prevention and treatment, but also a broad range of communitybased health services. The Administration's Global Health Initiative is helping partner countries achieve major advances through innovation, integration and improved health service delivery in countries."

Progress made in controlling malaria is still very fragile. The Global Fund to Fight AIDS, Tuberculosis and Malaria, the largest funder of malaria control programmes worldwide, will hold its third replenishment meeting in November 2010, where governments will make financial pledges which may well determine if the malaria-related MDGs can be achieved.

ABOUT RBM
Saving Lives with Malaria Control: Counting Down to the Millennium Development Goals is the third in the Progress & Impact Series of reports published by the RBM Partnership.

The Roll Back Malaria (RBM) Partnership is the global framework for coordinated action against malaria. It provides a neutral platform for consensus-building and developing solutions to challenges in the implementation of malaria control interventions and strategies. RBM is a public-private partnership that also facilitates the incubation of new ideas and lends support to innovative approaches.

The Partnership promotes high-level political commitment and keeps malaria high on the global agenda by enabling, harmonizing and amplifying partner-driven advocacy initiatives. Founded by UNICEF, WHO, the World Bank and UNDP and strengthened by the expertise, resources and commitment of more than 500 partner organizations, the Partnership secures policy guidance and financial and technical support for control efforts in countries and monitors progress towards universal goals.

For further information, please visit:
http://www.rollbackmalaria.org

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...